News Feed

  • Science Matters: Why Study Hydroxychloroquine? May 27, 2020

    By Susanna Naggie, MD, Vice Dean for Clinical Research at Duke University School of Medicine and Principal Investigator for the HERO-HCQ Trial

    From politicians to pre-prints and published observational studies, recent weeks have challenged research on hydroxychloroquine. In this dynamic and confusing landscape, we are sharing our rationale for studying hydroxychloroquine in the HERO-HCQ Trial — a randomized clinical trial of approximately 15,000 healthcare workers. It will test whether hydroxychloroquine can prevent COVID-19 ...

  • Early Science: What We Can Learn From the NEJM Study May 15, 2020

    By Anne Friedland, MD, Infectious Disease Program Fellow and Susanna Naggie, MD, Associate Professor of Medicine and Principal Investigator for the HERO-HCQ trial. (Both with the Duke School of Medicine.)

    Early in the COVID-19 pandemic, hydroxychloroquine was widely used for hospitalized patients. Over time the usage of hydroxychloroquine has declined, but use continues for the treatment of COVID-19. We do not have evidence to support its use for treatment or prevention of COVID-19, but multiple randomized clinical trials are in process. These trials are critical to ensuring that we have definitive answers. Until that time, ...

  • Respiratory Therapists: Heroes on the Front Line May 12, 2020

    Felix Khusid, RRT
    President of the New York Downstate Association for Respiratory Therapists and Administrative Director for a Respiratory Therapy Department in New York

    More than 100,000 respiratory therapists work in the United States caring for patients who have trouble breathing. These important frontline critical care workers, have been playing a pivotal role in managing mechanical ventilation for critically ill COVID-19 patients. 

    We spoke with Felix Khusid, RRT, a respiratory therapist working in New York, about his experiences with COVID-19

  • HERO Registry Town Hall: Shedding Light on the COVID-19 Pandemic for Healthcare Workers May 12, 2020

    HERO Registry leaders and stakeholders shared early learnings from our 11,000+ strong community of healthcare workers in our first Town Hall on Friday, May 8, 2020.

    Our first set of results include demographics of registry participants, the impact of the pandemic on the health of participants,concerns expressed such as antibody testing and immunity, access to personal protective equipment, and personal risk of virus exposure and transmission.

    A core principle of the HERO Registry is to share what we are learning with ...

  • HERO Registry: What We Are Learning So Far, April 29, 2020 May 5, 2020

    Emily O’Brien, PhD, FAHA, Duke Population Health Science
    Principal Investigator, HERO Registry

    Christopher B. Forrest, MD, PhD, Children’s Hospital of Philadelphia
    Chair, HERO Registry Sub-Committee

    The HERO Registry is off to a fantastic start! As of April 29th, 2020, 8,688 healthcare workers have joined the HERO community from all 50 states. Members of the HERO community work in all types of healthcare facilities from hospitals to hospices, skilled nursing facilities, primary care practices, radiology units, dialysis centers, and many more. Participants in the HERO ...

  • Early Science: What the VA Study Does (and Does Not) Tell Us May 4, 2020

    By Anne Friedland, MD, Infectious Disease Program Fellow and Susanna Naggie, MD, Associate Professor of Medicine and Principal Investigator for the HERO-HCQ trial. (Both with the Duke School of Medicine.)

    Our historical understanding of medicine and treatment is backed by carefully conducted research to prove what does – and doesn’t – work. Over the years, the scientific community has aligned on core responsibilities for those conducting research to ensure we consistently adhere to the highest standards in the design, conduct, and reporting of research. A key feature of research accountability is to ensure the results ...

  • Why We Need Randomized Controlled Trials Now April 24, 2020

    Adrian Hernandez, MD, MHS

    Principal Investigator, HERO Research Program

    In the middle of a pandemic it is natural for the public to want to quickly adopt what they perceive is the quickest cure. But therapies need to be tested rigorously enough to know if they work against COVID-19 and we need answers fast.

    Every day news is coming out – both good and bad – about hydroxychloroquine. But the ...

  • Understanding the Science: Evaluating the Research on Hydroxychloroquine So Far April 22, 2020

    By Anne Friedland, MD, Infectious Disease Program Fellow and Susanna Naggie, MD Associate Professor of Medicine and Principal Investigator for the HERO-HCQ trial. (Both with the Duke School of Medicine.)

    Information about whether hydroxychloroquine is useful to prevent or treat COVID-19 has been rapidly emerging and can be confusing. In this blog post, we will look at one of the first multi-center, randomized trials to assess the safety and efficacy of hydroxychloroquine compared to supportive treatment in people with COVID-19. This study was posted as a “pre-print” on April 14th 2020. That means the ...

  • Why I Want to Fight COVID-19 with the HERO Community April 22, 2020

    By Christopher B. Forrest, MD, PhD Children’s Hospital of Philadelphia Chair, HERO Registry Sub-Committee

    As a researcher who is involved in planning and leading the HERO Registry, the experiences I bring to this project are not just professional; they are personal. I am a physician and my 19-year-old son tested positive for the virus causing COVID-19 in early March. He was one of the first cases in our community, and probably exposed me and my wife to the virus. He ...

  • Healthcare Workers Across America Called to Join PCORnet® Study to Fight COVID-19 Together April 13, 2020

    HeroesResearch.org clinical research registry launches to answer crucial questions about the impact of novel coronavirus on healthcare workers’ lives

    DURHAM, N.C. (APRIL 13, 2020) – The Healthcare Worker Exposure Response & Outcomes (HERO) Registry launched today, inviting U.S. healthcare workers to share clinical and life experiences in order to understand the perspectives and problems faced by those on the COVID-19 pandemic front lines.

    The registry will unite America’s healthcare workers into a community to facilitate rapid-cycle research, including an upcoming large study of hydroxychloroquine’s effectiveness in preventing coronavirus infections in healthcare workers. The HERO ...